Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Nov 1;108(44):18144-9.
doi: 10.1073/pnas.1108416108. Epub 2011 Oct 24.

Mania-like behavior induced by genetic dysfunction of the neuron-specific Na+,K+-ATPase α3 sodium pump

Affiliations

Mania-like behavior induced by genetic dysfunction of the neuron-specific Na+,K+-ATPase α3 sodium pump

Greer S Kirshenbaum et al. Proc Natl Acad Sci U S A. .

Erratum in

  • Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2174

Abstract

Bipolar disorder is a debilitating psychopathology with unknown etiology. Accumulating evidence suggests the possible involvement of Na(+),K(+)-ATPase dysfunction in the pathophysiology of bipolar disorder. Here we show that Myshkin mice carrying an inactivating mutation in the neuron-specific Na(+),K(+)-ATPase α3 subunit display a behavioral profile remarkably similar to bipolar patients in the manic state. Myshkin mice show increased Ca(2+) signaling in cultured cortical neurons and phospho-activation of extracellular signal regulated kinase (ERK) and Akt in the hippocampus. The mood-stabilizing drugs lithium and valproic acid, specific ERK inhibitor SL327, rostafuroxin, and transgenic expression of a functional Na(+),K(+)-ATPase α3 protein rescue the mania-like phenotype of Myshkin mice. These findings establish Myshkin mice as a unique model of mania, reveal an important role for Na(+),K(+)-ATPase α3 in the control of mania-like behavior, and identify Na(+),K(+)-ATPase α3, its physiological regulators and downstream signal transduction pathways as putative targets for the design of new antimanic therapies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Exploration and ambulation in Myk/+ mice. Myk/+ show an increased number of explorations of (A) novel objects (+/+ mice n = 10, Myk/+ n = 11) and (B) nosepokes compared with +/+ mice and do not habituate (+/+ mice n = 8, Myk/+ n = 7). (C) In an open field Myk/+ travel a further distance and (D) spend more time in the center (+/+ mice n = 27, Myk/+ n = 22) in 5-min bins compared with +/+ mice. (E) Myk/+ exhibit unusual walking patterns compared with +/+ mice. (F) In 60 min in the open field, Myk/+ increase locomotor activity in response to d-amph, but +/+ mice do not (+/+ vehicle n = 9, +/+ d-amph n = 9; Myk/+ vehicle n = 8, Myk/+ d-amph n = 9). All data are presented as mean SEM, *P < 0.05, **P < 0.01, ***P < 0.001 compared with +/+ mice, ###P < 0.001 compared with Myk/+ vehicle mice.
Fig. 2.
Fig. 2.
Sleep and endogenous circadian period in Myk/+ mice. (A) Myk/+ (n = 6) experience more wake time than +/+ mice (n = 6) across 24 h with a reduction of both non-REM and REM sleep, as assessed by EEG and EMG. (B and C) Myk/+ show deficits in sleep duration only during the light phase; (D) Myk/+ have fewer REM sleep bouts but no change in non-REM bouts. (E) Non-REM bout length is reduced and REM bout length was unchanged in Myk/+. (F) REM sleep latency is reduced in Myk/+. (G) Wheel running actograms from +/+ and Myk/+ mice. Animals were held on a light-dark (LD) cycle for 14+ d, released into constant dark for 7 d to assess free running period, and reentrained to a LD12:12 cycle. Shaded area represents dark portion of LD cycle. Vertical arrows indicate continuation of nocturnal activity into light. (H) Endogenous period is extended in Myk/+ because of longer periods of (I) activity (α). All data are presented as means ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 compared with +/+ mice.
Fig. 3.
Fig. 3.
Mania-like behavior in Myk/+ mice. (A) Myk/+ prefer to explore the open arm of the EPM (+/+ mice n = 29, Myk/+ n = 19) and (B) the light side of the LDB (+/+ mice n = 27, Myk/+ n = 18) for longer durations than +/+ mice. (C) Myk/+ (n = 8) show a higher preference for 0.1% sucrose than +/+ mice (n = 16) over 4 d and (D) consume more sucrose on the first presentation of sucrose. W, water; S, sucrose. (E) Myk/+ (n = 14) are active for a longer duration than +/+ mice (n = 15) in the Porsolt forced swim test. (F) PPI scores are impaired in Myk/+ (n = 20) compared with +/+ mice (n = 33) at all prepulse intensities tested. (G and H) Myk/+ (n = 16) had a startle habituation deficit compared with +/+ when presented with a repeated auditory stimulus (n = 12). All data are presented as means ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 compared with +/+ mice.
Fig. 4.
Fig. 4.
Attenuation of mania-like behavior by lithium and VPA in Myk/+ mice. (A) Chronic treatment with lithium reduces total distance traveled by Myk/+ (n = 20) compared to untreated Myk/+ (n = 22) over 30 min in the open field and had no effect in +/+ mice (n = 28 control, n = 27 lithium). (B) VPA reduced total distance traveled by Myk/+ (n = 20) compared to vehicle-treated Myk/+ (n = 22), and had no effect on +/+ mice (n = 28 vehicle, n = 27 VPA) over 30 min. (C) Lithium reduces open-arm duration in Myk/+ (n = 18) compared with control Myk/+ (n = 19), but had no effect on +/+ mice (n = 29 control, n = 29 lithium) in the EPM. (D) VPA reduces open-arm duration in Myk/+ (n = 12) compared with vehicle-treated Myk/+ (n = 10) but had no effect on +/+ mice (n = 12 control, n = 12 VPA) in the EPM. (E) ERK inhibitor SL327 decreased distance traveled in Myk/+ (n = 12) compared with vehicle-treated Myk/+ (n = 9), and had no effect in +/+ mice (n = 12 vehicle, n = 12 SL327) in the open field. (F) SL327 reduced open-arm duration in Myk/+ (n = 6) compared with Myk/+ vehicle (n = 6) but had no effect on +/+ mice (n = 6 control, n = 6 SL327) in the EPM. (G) Rostafuroxin decreased distance traveled in Myk/+ (n = 12) compared with vehicle treatment (n = 12) and had no effect in +/+ mice (n = 13 vehicle, n = 15 rostafuroxin) in the open field. (H) In the EPM rostafuroxin reduced open arm duration in Myk/+ (n = 12) compared with vehicle treated Myk/+ (n = 12) and had no effect in +/+ mice (n = 12 vehicle, n = 15 rostafuroxin). All data are presented as means ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 compared with +/+ mice, #P < 0.05, ##P < 0.01, ###P < 0.001 compared with Myk/+ vehicle mice.
Fig. 5.
Fig. 5.
Free intracellular Ca2+ and Ca2+-dependent signaling in Myk/+ mice. (A) Mean resting intracellular ([Ca2+]i) is stably elevated in cortical cells cultured from Myk/+ (n = 47) than +/+ mice (n = 19), as measured by the ratio of fura-2 fluorescence emission upon 340-nm and 380-nm excitation (P < 0.01). (B) Myk/+ cortical neurons show a prolonged peak in [Ca2+]i compared with +/+ in response to bath superfusion of 10 μM glutamate (Glu). (C) When normalized to baseline [Ca2+]i, glutamate-evoked [Ca2+]i transients were prolonged in neurons from Myk/+ compared with neurons from +/+ (D) Immunoreactivity of p-Akt1/2/3 and p-ERK1/2 was elevated in Myk/+ compared with +/+ hippocampus. Transgenic overexpression of NKA α3 in Myk/+/Tg mice did not alter hippocampal levels of p-ERK1/2 but reduced p-Akt1/2/3. +/+, n = 8 (Akt, ERK); Myk/+, n = 11 (Akt), n = 10 (ERK); Myk/+/Tg, n = 5 (Akt, ERK). (E) Model of NKA α3 signaling at the synapse in +/+ and Myk/+ mice. Myk/+ mice have reduced NKA activity that augments [Ca2+]i and activation of p-ERK and p-Akt. These intracellular signals may independently, additively or synergistically contribute to behavioral phenotypes of mania. All data are presented as means ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 compared with +/+ mice, ++P < 0.01 compared with Myk/+/Tg mice.

References

    1. Goldstein I, et al. Association between sodium- and potassium-activated adenosine triphosphatase alpha isoforms and bipolar disorders. Biol Psychiatry. 2009;65:985–991. - PubMed
    1. Dobretsov M, Stimers JR. Neuronal function and alpha3 isoform of the Na/K-ATPase. Front Biosci. 2005;10:2373–2396. - PubMed
    1. Croyle ML, Woo AL, Lingrel JB. Extensive random mutagenesis analysis of the Na+/K+-ATPase alpha subunit identifies known and previously unidentified amino acid residues that alter ouabain sensitivity—Implications for ouabain binding. Eur J Biochem. 1997;248:488–495. - PubMed
    1. Schoner W, Scheiner-Bobis G. Endogenous and exogenous cardiac glycosides and their mechanisms of action. Am J Cardiovasc Drugs. 2007;7:173–189. - PubMed
    1. Urayama O, Sweadner KJ. Ouabain sensitivity of the alpha 3 isozyme of rat Na,K-ATPase. Biochem Biophys Res Commun. 1988;156:796–800. - PubMed

Publication types

Substances